WallStreetZenWallStreetZen

NYSE: SNN
Smith & Nephew PLC Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Be the first to know when Wall Street analysts revise their SNN stock forecasts and price targets.

Forecast return on equity

Is SNN forecast to generate an efficient return?
Company
N/A
Industry
-0.02%
Market
19.68%

Forecast return on assets

Is SNN forecast to generate an efficient return on assets?
Company
N/A
Industry
-0.02%

SNN revenue forecast

What is SNN's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$5.8B+4.92%
Avg 2 year Forecast
$6.2B+11.19%
Avg 3 year Forecast
$6.5B+17.43%
SNN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SNN earnings growth forecast

How is SNN forecast to perform vs Medical Devices companies and vs the US market?
Company
139.2%
Industry
32.87%
Market
28.56%
SNN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Industry Forecast
SNN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Market Forecast
SNN's earnings are forecast to... subscribe to Premium to read more.
Forecast Earnings Growth vs Savings Rate Forecast

SNN revenue growth forecast

How is SNN forecast to perform vs Medical Devices companies and vs the US market?
Company
5.44%
Industry
8.62%
Market
9.3%
SNN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SNN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SNN vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
SNN$24.80N/AN/A
BRKR$82.46$85.67+3.89%Buy
PODD$167.27$224.67+34.31%Buy
SWAV$328.54$313.71-4.51%Buy
BIO$285.28$421.67+47.81%Buy
View Top Medical Device Stocks

Smith & Nephew Stock Forecast FAQ

What is SNN's revenue growth forecast for 2024-2026?

(NYSE: SNN) Smith & Nephew's forecast annual revenue growth rate of 5.44% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.3%.

Smith & Nephew's revenue in 2024 is $5,549,000,000.On average, 2 Wall Street analysts forecast SNN's revenue for 2024 to be $5,109,845,234,452, with the lowest SNN revenue forecast at $5,098,470,596,998, and the highest SNN revenue forecast at $5,121,219,871,905. On average, 1 Wall Street analysts forecast SNN's revenue for 2025 to be $5,415,240,207,310, with the lowest SNN revenue forecast at $5,415,240,207,310, and the highest SNN revenue forecast at $5,415,240,207,310.

In 2026, SNN is forecast to generate $5,718,914,941,788 in revenue, with the lowest revenue forecast at $5,718,914,941,788 and the highest revenue forecast at $5,718,914,941,788.

If you're new to stock investing, here's how to buy Smith & Nephew stock.

What is SNN's forecast return on assets (ROA) for 2024-2026?

(NYSE: SNN) forecast ROA is N/A, which is lower than the forecast US Medical Devices industry average of -0.02%.

What is SNN's forecast return on equity (ROE) for 2024-2026?

(NYSE: SNN) forecast ROE is N/A, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.